A number of successful systemic therapies are available for treatment of disseminated cancers. However, tumor response is often transient and therapy frequently fails due to emergence of resistant populations. The latter reflects the temporal and spatial heterogeneity of the tumor microenvironment as well as the evolutionary capacity of cancer phenotypes to adapt to therapeutic perturbations. Although cancers are highly dynamic evolutionary systems, cancer therapy is typically administered according to a fixed, linear protocol. Alternative "evolutionarily enlightened" therapeutic strategies including adaptive therapy and double bind therapy will be discussed. These approaches emphasize the phenotypic cost of resistance to therapy and attempt to prevent or exploit this cost using evolutionary principles similar to those developed in applied ecology for pest management. Adaptive therapy evolves in response to the temporal and spatial variability of tumor microenvironment and cellular phenotype as well as therapy-induced perturbations. The goal of adaptive therapy is to enforce a stable tumor burden by permitting a significant population of chemosensitive cells to survive so that they, in turn, suppress proliferation of the less-fit but chemo-resistant subpopulations. Double bind therapy is one which requires a phenotypic adaptation that compromises the cancer cells' ability to proliferate. This is the equivalent of using predators or parasites to control proliferation of invasive pests. Mathematical models and preliminary experimental evidence for these strategies will be presented.
